No abstract

Non-CDC High Risk 4316 (88.5%) 16 (0.3%) 171 (3.5%) 17 (0.4%) 243 (5.6%) TOTAL 4877 21 (0.4%) 248 (5.0%) 22 (0.5%) 309 (6.3%) *CDC High Risk was determined by screening questions only, other CDC recommended screening including physical assessment fi ndings, hemodilution etc. were not included in this analysis. ** p< .000121/4877 (0.4%) potential donors tested HIV-1/2 antibody positive. The incidence in the CDC-HR group was 5/561 (0.9%) vs.16/4316 (0.3%) in the Non-CDC HR group (p= 0.15). The incidence of HCV+ tests in the CDC-HR group was 77/561 (13.7%) as compared to 171/4316 (3.5%) in the Non-CDC-HR group (p<.0001). The incidence of HBsAg + tests in the CDC-HR was 0.9% vs. 0.4% in the Non-CDC HR group (p=.18). The incidence of HB Ab+ tests in the CDC HR group was 66/561 (12%) vs. 243/4316 (5.6%) in the Non-CDC HR group (P<.0001). Summary and Conclusions: There was a trend for higher incidence of positive serology for all tests in the CDC HR group but this was signifi cant only for HCV and HB c Ab. The majority of positive cases for each of the tests were in the non High Risk group. These data need further confi rmation and should be considered when contemplating routine prospective NAT testing for potential organ donors. Considerations of logistics, cost and potential inadvertent loss of donors and organs associated with prospective NAT testing need to be weighed against the current low incidence of disease transmission.

No abstract